Drug Trial Radar · NCT05746559
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
555
Actual
Start
Apr 6, 2023
Primary completion
Oct 7, 2025
Study completion May 7, 2026
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Conditions
- Chronic Kidney Disease
- CKD
- Cardiac Disease
- Cardiopulmonary Bypass
Interventions
PlaceboDrug
Participants will receive a single weight-based dose of placebo via intravenous infusion.
RavulizumabDrug
Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estimated Percentage of Participants Who Experienced Major Adverse Kidney Events (MAKE, Based on Serum Cystatin C [sCysC)] at Day 90 Post-CPB (MAKE90)Time frame: Day 90 post-CPB (surgery with CPB was within 7 days after study drug administration on Day 1)
Locations
130 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Orange, California
Research Site
San Francisco, California
Research Site
Stanford, California
Research Site
Chicago, Illinois
Research Site
Boston, Massachusetts
Research Site
Springfield, Massachusetts
Research Site
Kansas City, Missouri
Research Site
Rochester, New York
Research Site
Valhalla, New York
Research Site
Fargo, North Dakota
Research Site
Philadelphia, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Dallas, Texas
Research Site
Charlottesville, Virginia
Research Site
Richmond, Virginia
Research Site
Seattle, Washington
Research Site
Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Corrientes, Argentina
Research Site
Santa Fe, Argentina
Research Site
Brisbane, Australia
Research Site
Monash, Australia
Research Site
Murdoch, Australia
Research Site
Southport, Australia
Research Site
Belo Horizonte, Brazil
Research Site
Fortaleza, Brazil
Research Site
Recife, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
Saint John, New Brunswick, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.